Expression prevalence and dynamics of GPCR somatostatin receptors 2 and 3 as cancer biomarkers beyond NET: a paired immunohistochemistry approach.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
27 Nov 2023
27 Nov 2023
Historique:
received:
07
06
2023
accepted:
16
11
2023
medline:
29
11
2023
pubmed:
28
11
2023
entrez:
27
11
2023
Statut:
epublish
Résumé
Somatostatin receptors are clinically validated GPCR biomarkers for diagnosis and treatment of various neuroendocrine tumors (NET). Among the five somatostatin receptors, SST2 and SST3 are associated with apoptosis and cell cycle arrest, making these receptor subtypes better differentiated targets in precision oncology. In this study we performed immunohistochemistry of paired tissue microarrays containing 1125 cores, representing 43 tumor types, each stained for SST2 and SST3. A 12-point immunoreactive scoring (IRS) range was used for interpretation of the staining results. We analyzed the results twice, using the conventional positivity IRS cutoffs ≥ 3 and more stringent ≥ 6. Evaluation of receptors expression dynamics was performed for tumor-nodes-metastases (TNM) defined subgroups (ovarian and hepatocellular adenocarcinomas) as a function of their tumor stage. Our results indicate that two-thirds of tested cores exhibit clinically significant expression of at least SST2 or SST3 (IRS ≥ 6). The expression prevalence of both receptors tends to decline with tumor progression. However, an unexpected upregulation of both SST2 and SST3 reemerged in metastases suggesting conserved receptors genetic potential during tumor life cycle. We suggest that SST2 and SST3 should be further explored as potential biomarkers and therapeutic tools for maximizing the efficiency of somatostatin-based precision oncology of solid tumors beyond NET.
Identifiants
pubmed: 38012197
doi: 10.1038/s41598-023-47877-0
pii: 10.1038/s41598-023-47877-0
pmc: PMC10682014
doi:
Substances chimiques
somatostatin receptor 2
D73QL0OMU2
Receptors, Somatostatin
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20857Informations de copyright
© 2023. The Author(s).
Références
Neuroendocrinology. 2022;112(4):358-369
pubmed: 34077939
Biochim Biophys Acta. 2011 Mar;1813(3):390-402
pubmed: 21194548
Curr Drug Targets. 2016;17(5):529-37
pubmed: 26951062
Front Oncol. 2021 Mar 03;11:630827
pubmed: 33747951
J Clin Endocrinol Metab. 1997 Jun;82(6):1857-62
pubmed: 9177396
Arch Pathol Lab Med. 2014 May;138(5):595-601
pubmed: 24236805
N Engl J Med. 1997 Jan 23;336(4):263-5
pubmed: 8995089
Methods Mol Biol. 2010;664:113-26
pubmed: 20690058
Endocrinology. 1996 Sep;137(9):4046-9
pubmed: 8756582
Biopolymers. 2015 Nov;104(6):743-52
pubmed: 26058565
J Clin Endocrinol Metab. 2008 Nov;93(11):4519-24
pubmed: 18697876
Cells. 2021 Nov 24;10(12):
pubmed: 34943797
Gynecol Oncol. 2002 Feb;84(2):235-40
pubmed: 11812080
Pharmaceutics. 2022 Jul 01;14(7):
pubmed: 35890290
Nat Rev Cancer. 2016 Aug;16(8):525-37
pubmed: 27388699
World J Surg. 2001 Apr;25(4):407-12
pubmed: 11344389
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Breast Cancer Res Treat. 2005 Jul;92(2):175-86
pubmed: 15986128
J Vis Exp. 2014 Sep 23;(91):51893
pubmed: 25285857
Breast Care (Basel). 2015 Jul;10(3):173-8
pubmed: 26557822
Mol Cell Endocrinol. 2010 Sep 15;326(1-2):89-98
pubmed: 20438803
Endocrinology. 2003 Apr;144(4):1574-84
pubmed: 12639942
Diagn Pathol. 2010 Jul 07;5:48
pubmed: 20609235
Asian Pac J Cancer Prev. 2013;14(7):4071-5
pubmed: 23991955
Yale J Biol Med. 1997 Sep-Dec;70(5-6):471-9
pubmed: 9825475
Ann Oncol. 2001;12 Suppl 1:S81-7
pubmed: 11521727
J Mol Signal. 2012 May 31;7(1):5
pubmed: 22651821
J Clin Endocrinol Metab. 2017 Sep 1;102(9):3581-3590
pubmed: 28911153
Endocrine. 2018 Feb;59(2):426-437
pubmed: 29196939
Surgery. 2019 Jan;165(1):64-68
pubmed: 30415874
Int J Clin Exp Pathol. 2012;5(3):187-94
pubmed: 22558472
Oncol Lett. 2019 Feb;17(2):1723-1731
pubmed: 30675231
Biochem Biophys Res Commun. 1993 Apr 15;192(1):288-94
pubmed: 8386508
BMC Cancer. 2022 Jul 7;22(1):740
pubmed: 35799158
Clin Cancer Res. 2020 Feb 15;26(4):957-969
pubmed: 31624102
Cell. 2018 Jan 11;172(1-2):41-54.e19
pubmed: 29249361
Hum Pathol. 2019 Apr;86:66-75
pubmed: 30529752
Endocrinology. 2001 Jan;142(1):477-86
pubmed: 11145612
Eur J Nucl Med. 2001 Jul;28(7):836-46
pubmed: 11504080
J Endocrinol. 2016 Nov;231(2):135-145
pubmed: 27587848
Endocr Relat Cancer. 2015 Feb;22(1):111-9
pubmed: 25515731
J Biol Chem. 2001 Apr 27;276(17):14027-36
pubmed: 11134004
BMC Cancer. 2017 Dec 28;17(1):896
pubmed: 29282035
Front Endocrinol (Lausanne). 2021 May 19;12:679000
pubmed: 34093445
Neuroendocrinology. 2018;106(2):116-127
pubmed: 28384628
Diagn Pathol. 2014 Nov 29;9:221
pubmed: 25432701
Endocr Relat Cancer. 2008 Sep;15(3):701-20
pubmed: 18524947
Cancer Treat Rev. 2021 Feb;93:102141
pubmed: 33418096
Int J Mol Sci. 2021 Nov 12;22(22):
pubmed: 34830137
N Engl J Med. 1996 Jan 25;334(4):246-54
pubmed: 8532003
J Neuroendocrinol. 2001 Mar;13(3):279-87
pubmed: 11207943
Molecules. 2018 Jun 26;23(7):
pubmed: 29949880
J Biol Chem. 2004 Aug 27;279(35):36179-83
pubmed: 15231824
J Mol Endocrinol. 2014 Jun;52(3):R223-40
pubmed: 24647046
Pancreas. 2010 Nov;39(8):1155-66
pubmed: 20531241
Regul Pept. 2013 Nov 10;187:35-41
pubmed: 24188818
Virchows Arch. 2002 May;440(5):461-75
pubmed: 12021920
J Clin Endocrinol Metab. 2019 Jun 1;104(6):2083-2093
pubmed: 30657933
Eur J Nucl Med. 1993 Aug;20(8):716-31
pubmed: 8404961
Methods Enzymol. 2014;534:261-80
pubmed: 24359959
Neuroendocrinology. 2012;95(3):232-47
pubmed: 22156600
Acta Pharmacol Sin. 2004 Oct;25(10):1380-6
pubmed: 15456543
J Histochem Cytochem. 2019 Oct;67(10):735-743
pubmed: 31381461
Curr Opin Cell Biol. 2014 Apr;27:126-35
pubmed: 24508914
Front Pediatr. 2022 Mar 10;10:836230
pubmed: 35359899
Hum Pathol. 2015 Mar;46(3):390-6
pubmed: 25554089
Neuroendocrinology. 2011;94(3):255-64
pubmed: 21952553
Pathologe. 1987 May;8(3):138-40
pubmed: 3303008
Neuroendocrinology. 2012;96(4):301-10
pubmed: 22414742
Chin J Cancer. 2011 Jan;30(1):1-4
pubmed: 21192839